Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bevision

BeVision SIGNED

Better vision after cataract and refractive surgery with photonics technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BeVision project word cloud

Explore the words cloud of the BeVision project. It provides you a very rough idea of what is the project "BeVision" about.

generating    million    actual    clouding    select    imperfections    track    patient    optical    optimisation    aberrations    record    clinically    refractive    age    people    understand    billion    4m    revenue    skills    vao    interoperable    as    2025    fast    figure    cumulative    simulate    solutions    refine    outcome    vision    commercialisation    validate    rapid    clinical    adaptive    dramatically    market    introduction    outcomes    lenses    post    ophthalmic    objectively    satisfied    forehand    half    helping    device    disruptive    profit    aging    eyesight    eye    patients    suffer    intraocular    institutes    4    cataracts    swiftly    disrupt    prepare    assembled    correcting    lens    65    surgeries    innovation    cataract    solid    successful    6m    manufactures    world    operation    simulator    solution    36    protocols    commercial    bevision    laser    population    medical    correct    200    software    optics    business    doctor    competitive    older    effect    validation    surgery    visual    ophthalmology    subsequently    voptica    benefit   

Project "BeVision" data sheet

The following table provides information about the project.

Coordinator		 VOPTICA S.L. 

Organization address
address: CAMPUS DE ESPINARDO, CTRA. MADRID KM.388, PARQUE CIENTIFICO DE MURCIA. EDIFICIO T. LOCALES T1/3 Y T2/9
city: MURCIA
postcode: 30100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.voptica.com
 Total cost 2˙486˙788 €
 EC max contribution 1˙740˙751 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VOPTICA S.L. ES (MURCIA) coordinator 1˙740˙751.00

Map

 Project objective

As we get older, we all will develop eyesight problems. Around the age of 65 more than half of us suffer from eye lens clouding, or cataracts. Cataract surgery is now the most common operation in Europe, with 4.3 million people getting treated each year, a figure that will only increase due to our fast aging population. However, 200,000 of them are not satisfied with the outcome of their eye correcting surgeries as they can’t experience on forehand what their vision will be. Voptica has developed the Visual Adaptive Optics (VAO) simulator, a disruptive innovation in eye testing, allowing patients to experience the effect of intraocular lenses or laser surgery on their vision before the actual operation, helping the patient and doctor to select their best solution and understand what their vision will be like post-surgery.

Our technology is used by world-leading research institutes and lens-manufactures, but to prepare VAO for clinical market introduction our project BeVision will refine its software protocols, make it interoperable and clinically validate the technology. After a successful clinical validation, VAO will be the only medical device in the world that can measure objectively all eye aberrations of patients and, subsequently, simulate the different optical solutions to correct the patient’s eye imperfections during visual testing. Our technology will dramatically improve the outcomes of cataract and laser refractive surgeries.

Our highly competitive technology can swiftly disrupt the $4.4 billion ophthalmology device market, generating a rapid business growth for Voptica, with a cumulative revenue of € 36.4m and a profit of € 8.6m by 2025.

To make BeVision a commercial success, we have assembled a consortium with a solid track record in the development, optimisation, clinical validation and commercialisation of ophthalmic devices and have all the skills and resources for its commercial exploitation to benefit our business and Europe.

 Deliverables

List of deliverables.
WP4 Scientific publications Documents, reports 2020-03-09 16:07:04

Take a look to the deliverables list in detail:  detailed list of BeVision deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BEVISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BEVISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More